Current Edition

Upcoming Events

Advertisement

news

Two cancer cell therapy studies succeeded. Why did a third fail?

In two major clinical trials, researchers found cell therapy dramatically outperformed the standard of care used for the past few decades to counter a common type of ...
Continue Reading →
news

Roche bets big on off-the-shelf cancer cell therapy with Adaptimmune deal

Adaptimmune, like companies such as Bluebird Bio and Cellectis, remains one of the more prominent independent developers of cancer cell therapies. Early pioneers Kite...
Continue Reading →